David Hallal

David Hallal

Advisor

Executive Partners

Cambridge Office

David Hallal currently serves as an MPM Advisor and CEO of ElevateBio, an MPM portfolio company that is developing a portfolio of cell and gene therapy subsidiaries to treat cancer and other incurable diseases. He is also CEO of AlloVir (NASDAQ: ALVR), an ElevateBio portfolio company developing innovative allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies.

David brings nearly 30 years of senior executive leadership experience in growing and operating several successful biotechnology companies to his role at MPM. He also serves as Chairman of the Board at iTeos Therapeutics (NASDAQ: ITOS), an MPM portfolio company, and Scholar Rock, and is a member of the Board of Directors at Seer.

Prior to MPM, he spent more than 10 years at Alexion Pharmaceuticals where he played a central role in transforming the then pre-commercial company into a successful commercial company with more than $3 billion in annual revenues. As the CEO of Alexion, he expanded the pipeline from a single-product to a multi-product enterprise and was responsible for overseeing key product development milestones including the highly successful launch of Strensiq® and the rapid 18-month advancement of Alexion’s highest value pipeline candidates from preclinical to registration trials for multiple diseases. Prior to his appointment as CEO, he served as Alexion’s Chief Operating Officer and then its Chief Commercial Officer and built the company’s commercial infrastructure and a 50-country operating platform to support the launch of Soliris® for the treatment of Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, which resulted in the successful commercialization of an ultra-orphan drug in the biotechnology industry. Prior to Alexion, he held commercial leadership positions at Amgen, Biogen and Eyetech Pharmaceuticals where he was responsible for the launch and adoption of first-in-class products in hematology, oncology, nephrology, immunology, and ophthalmology.

David received his B.A. in Psychology from the University of New Hampshire.